Effect of ethanol on opioid drug permeability through caco-2 cell monolayers

AAPS Journal

Volumn 10, Issue 2, 2008, Pages 360-362

  Volpe, Donna A ^a   Asafu Adjaye, Ebenezer B ^a   Ellison, Christopher D ^a   Doddapaneni, Suresh ^a   Uppoor, Ramana S ^a   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Caco 2; Ethanol; Hydromorphone; Oxycodone; Oxymorphone; Permeability

Indexed keywords

ALCOHOL; ATENOLOL; HYDROMORPHONE; METOPROLOL TARTRATE; OPIATE; OXYCODONE; OXYMORPHONE;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ALCOHOL INTERACTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; HUMAN; HUMAN CELL; INTESTINE MUCOSA PERMEABILITY; MAXIMUM PLASMA CONCENTRATION; MONOLAYER CULTURE;

ANALGESICS, OPIOID; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; HUMANS;

EID: 53849084105     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9046-3     Document Type: Article

References (18)

1. A. G. Fraser. Pharmacokinetic interactions between alcohol and other drugs. Clin. Pharmacokinet. 33: 79-90 (1997).
2. E. M. Sellers, and M. R. Holloway. Drug kinetics and alcohol ingestion. Clin. Pharmacokinet. 3: 440-452 (1978).
3. A. Pfeiffer, B. Hogl, and H. Kaess. Effect of ethanol and commonly ingested alcoholic beverages on gastric emptying and gastrointestinal transit. Clin. Investig. 70: 487-491 (1992).
4. M. Linnoila, M. J. Mattila, and B. S. Kitchell. Drug interactions with alcohol. Drugs. 18: 299-311 (1979).
5. J. Persson. Alcohol and the small intestine. Scand. J. Gastroenterol. 26: 3-15 (1999).
6. L. R. Draper, L. A. Gyure, J. G. Hall, and D. Robertson. Effect of alcohol on the integrity of the intestinal epithelium. Gut. 24: 399-404 (1983).
7. A. Tarnawski, D. Hollander, and H. Gergely. Ethanol-induced gastric mucosal injury: Sequential analysis of morphologic and functional changes. Gastroenterol. Clin. Biol. 9: 88-92 (1995).
8. T. Y. Ma, D. Nguyen, V. Bui, H. Nguyen, and N. Hoa. Ethanol modulation of intestinal epithelial tight junction barrier. Am. J. Physiol. 276: G965-G974 (1999).
9. G. Sathyan, K. Sivakumar, and J. Thipphawong. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr. Med. Res. Opin. 24: 297-305 (2008).
10. H. R. Wallage, and J. P. F. P. Palmentier. Hydromorphone-related fatalities in Ontario. J. Anal. Toxicol. 30: 202-209 (2006).
11. Product Information: Opana® ER Oxymorphone Hydrochloride Extended-Release Tablets. Endo Pharmaceuticals Inc. Chadds Ford, Pennsylvania 19317. July 2006. PDR® Electronic Library™, accessed 12/06/07.
12. W. D. Fiske, G. Photivihok, and I. H. Benedek. The effects of graded concentrations of oral ethanol on the in vivo bioavailability of oxymorphone HCl extended release (ER) tablets. Clin. Pharmacol. Ther. 81 (suppl 1):S112 (2007), (abstract PIII-83).
13. M. Abdelhameed, M. Guirguis, J. Van Berkum, R. Chaouki, J. Jenkins, P. Perrino, S. Harris, D. Cilla, and A. Kristensen. Effect of varying concentrations of ethanol administration on the pharmacokinetics (PK) of oxycodone melt extrusion multiparticulate (OCM) 10-mg capsule + naltrexone melt extrusion multiparticulate (NXM) 8-mg capsule in the fasted state in normal healthy subjects [abstract]. AAPS J. 81 (suppl 2):W4385 (2006).
14. Product Information: Oxycontin® Oxycodone HCl Controlled-Release Tablets Purdue Pharma L.P., Stamford, CT. May 31, 2005. PDR® Electronic Library™, accessed 12/06/07.
15. J. J. Vallner, J. T. Stewart, J. A. Kotzan, E. B. Kirsten, and I. L. Honigberg. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J. Clin. Pharmacol. 21: 152-156 (1981).
16. D. A. Volpe, A. B. Ciavarella, E. B. Asafu-Adjaye, C. D. Ellison, P. J. Faustino, L. X. Yu, and A. S. Hussain. Classification of drug permeability with a Caco-2 cell monolayer assay. Clin. Res. Regul. Affairs. 24: 39-47 (2007).
17. S. Yamashita, T. Furubayashi, M. Kataoka, T. Sakane, H. Sezaki, and H. Tokuda. Optimized conditions for intestinal drug permeability using Caco-2 cells. Eur. J. Pharm. Sci. 10: 194-204 (2000).
18. G. M. Pauletti, K. L. Audus, and I. J. Hidalgo. Effect of co-solvents on the physical barrier properties of Caco-2 cell monolayers [abstract]. Pharm. Sci. 1 (1):182 (1998).